Skip to Page Content
Note: All information and materials provided has expired for CME credit possibilities and is solely to be used for informational purposes only.



Clinical and laboratory observations indicate that drug-induced weight loss is accompanied by significant changes in eating behavior. The Eating Behavior Questionnaire (EBQ)—a newly designed tool for measuring treatment-induced eating behavior change—will be presented and discussed during this lecture. Clinical data reveals that untreated patients have high EBQ scores, that treated patients have significantly lower EBQ scores, and that EBQ scores drop quickly and dramatically after treatment initiation.

Disclosures (at time of recording):


  • Ed J. Hendricks, MD, MFOMA: Eurodrug Laboraties: Speaker; Akrimax Pharmaceuticals: Speaker; VIVUS: Speaker: Citius Pharmaceuticals, LLC: Consultant; GLG Healthcare & Biomedical Council: Consultant


  • William McCarthy, MD, FOMA: Ridgetop Research: Offered Expert Opinion on Qsymia

  • Craig Primack, MD, FACP, FOMA: Nestle: Speaker, Focus Group Member; VIVUS: Speaker, Consultant; Diet Owl Smart Phone Application: Founder

  • Nothing to Disclose: Michael Bateman, DO; Crystal Broussard, MD; Sandra Christensen, MSN, ARNP, FOMA; Krishna Doniparthi, MD, FOMA; Brent Gear, DO; Charles Halliman; Deborah Bade Horn, DO, MPH, MFOMA; Carl Knopke, MD, FOMA; Richard Lindquist, MD, ABFM, FAASP, FOMA; Dana Mansell; Jeremy McConnell, MD, FOMA; Timothy McCormick, DO, MPH; Daisy Merey, MD, PhD; Scott Rigden, MD, FAAFP, MFOMA; Stacy Schmidt, PhD; Jennifer Seger, MD, FOMA; Harold Seim, MD, MPH, FOMA; Laurie Traetow, CAE, CPA; J. Warren Willey, DO

Presentation Information
Presentation Date:
June 20, 2017
Expiration Date:
December 31, 2020 11:55 PM
Presentation Objectives
  • Use an eating behavior questionnaire to measure treatment-induced changes in eating patterns.
The Eating Behavior Questionnaire: A Novel Clinical Examination

(Speaker biography at time of recording)

ABOM Diplomate

Dr. Ed Hendricks is the medical director for the Centers for Weight Management in Roseville, Calif. and Sacramento, Calif. He is a member of the Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drug Advisory Committee, a panel of experts that advises the FDA on obesity drugs. He is a prominent speaker and researcher for the Obesity Medicine Association. Through his research, Dr. Hendricks has demonstrated that anti-obesity drugs can help effectively treat various diseases, including type 2 diabetes, heart disease, hypertension, sleep apnea, and several types of cancer. Dr. Hendricks is the Chairman of the Obesity Treatment Foundation.

Individual topic purchase: Selected
Share This
Preview The Eating Behavior Questionnaire: A Novel Clinical ExaminationPreview The Eating Behavior Questionnaire: A Novel Clinical Examination
All Access Subscription
Use for All Access  account holders only
To continue, you need to log in to oma. If you have any questions about your account please contact us at 1-866-702-3278.
Email Address:
OMA Member Price: